The Neuroscience of Being Human

The Neuroscience of Antidepressants

What SSRIs actually do at the synapse, why the therapeutic delay matters more than anyone told you, and how the next generation of antidepressants may work through entirely different mechanisms

1,305-word article with 8 Harvard references.

What an SSRI actually does in the first twenty-four hours

When a person swallows their first SSRI tablet, the drug is absorbed through the gut, crosses the blood-brain barrier, and arrives at serotonergic synapses throughout the brain. There, it binds to the serotonin transporter, a protein embedded in the membrane of the presynaptic neuron whose job is to hoover serotonin back out of the synaptic cleft after it has been released. With the transporter blocked, serotonin accumulates in the cleft and remains available to bind to postsynaptic receptors for longer. Within a few hours, serotonin levels in the synapse have measurably increased (Stahl, 2013).

And yet the person does not feel better. Often they feel worse. The initial increase in serotonin activates autoreceptors on the presynaptic neuron, specifically the 5-HT1A somatodendritic receptors, which act as a braking mechanism. These autoreceptors detect the elevated serotonin and respond by reducing the neuron's firing rate. The net effect in the first week is that the serotonin system partially compensates for the drug's action, which is one reason why the early days of SSRI treatment can involve increased anxiety, nausea, and emotional turbulence. The brain is pushing back against the chemical change.

The two-to-four-week mystery

Over the following weeks, the autoreceptors desensitise. They stop responding to the elevated serotonin with the same vigour, and the presynaptic neuron begins firing normally again. Now the increased serotonin in the cleft is no longer being counteracted, and the downstream effects begin to accumulate. But the clinical improvement that patients report after two to four weeks does not map neatly onto autoreceptor desensitisation alone. Something else is happening.

Ronald Duman and Lisa Monteggia proposed that the real therapeutic action of antidepressants is neurotrophic. SSRIs, through a signalling cascade that involves increased cAMP, activation of the CREB transcription factor, and enhanced gene expression, increase the production of brain-derived neurotrophic factor. BDNF does not alter mood directly. It supports synaptic plasticity, promotes the survival and growth of neurons, and facilitates neurogenesis in the dentate gyrus of the hippocampus. In essence, the antidepressant does not make the brain happier. It makes the brain more capable of changing, and it is the change, driven by the person's ongoing experience, therapy, social connection, and daily functioning, that produces the improvement in mood (Duman and Monteggia, 2006).

Ketamine and the glutamate revolution

In 2006, Carlos Zarate and colleagues at the National Institute of Mental Health published a study that startled the field. A single intravenous infusion of ketamine, a dissociative anaesthetic that blocks NMDA glutamate receptors, produced significant antidepressant effects within two hours in patients with treatment-resistant depression. Some of these patients had failed to respond to multiple conventional antidepressants. Ketamine worked where everything else had not, and it worked fast (Zarate et al., 2006).

The mechanism appears to involve a rapid burst of synaptogenesis. By blocking NMDA receptors on GABAergic interneurons, ketamine disinhibits glutamatergic pyramidal neurons in the prefrontal cortex, producing a surge of glutamate release that activates AMPA receptors and triggers a cascade of intracellular signalling. The end result is a rapid increase in BDNF release and the formation of new dendritic spines, the tiny protrusions on neurons where synaptic connections are made. In animal models, the density of these spines increases within hours of ketamine administration and remains elevated for days. The drug is not altering mood directly. It is rebuilding the synaptic infrastructure that chronic stress had eroded.

Psilocybin and the disruption of rigid self-reference

Robin Carhart-Harris and colleagues at Imperial College London used functional MRI to examine the brain during psilocybin-assisted therapy for treatment-resistant depression. They found that psilocybin produced a marked decrease in activity within the default mode network, particularly the medial prefrontal cortex and the posterior cingulate cortex. These regions are hyperactive in depression and are associated with the repetitive, self-referential rumination that characterises the condition. Psilocybin appeared to temporarily loosen the grip of these rigid patterns, allowing the brain to enter states of connectivity that are normally inaccessible (Carhart-Harris et al., 2017).

Patients described the experience as gaining perspective on their depression, seeing it from the outside rather than being trapped within it. The neuroimaging supported their accounts: post-treatment scans showed increased connectivity between brain regions that had previously been functionally isolated, suggesting that the brain had reorganised itself into a less rigid, more flexible configuration. The effects persisted for weeks after a single session. Psilocybin is not an antidepressant in the conventional sense. It does not need to be taken daily. It appears to work by creating a window of neuroplasticity during which the brain can escape its depressive attractor state.

The lesson from ketamine, psilocybin, and the limitations of SSRIs is the same: depression is not a chemical deficit that needs topping up. It is a state of reduced neural flexibility in which the brain has become locked into patterns of connectivity that sustain low mood, withdrawal, and negative self-reference. Effective antidepressants, whatever their mechanism, work by restoring the brain's capacity to change. The pill does not cure the depression. It gives the brain the tools to cure itself, provided the person's environment, relationships, and therapeutic support give it somewhere better to go.